Please use this identifier to cite or link to this item:
Title: Early miR-223 Upregulation in Gastroesophageal Carcinogenesis
Authors: Fassan, Matteo;Saraggi, Deborah;Balsamo, Laura;Realdon, Stefano;Scarpa, Marco;Castoro, Carlo;Coati, Irene;Salmaso, Roberta;Farinati, Fabio;Guzzardo, Vincenza;Arcidiacono, Diletta;Munari, Giada;Gasparini, Pierluigi;Veronese, Nicola;Luchini, Claudio;Valeri,
subject: AHA Scientific Statements;Acute limb ischemia;Antiplatelet agents;Bypass surgery;Claudication;Critical limb ischemia;Endovascular procedures;Limb salvage;Peripheral artery disease;Smoking cessation;Supervised exercise
Year: 2017
Abstract: Objectives To test miR-223 upregulation during gastric (intestinal-type) and Barrett esophageal carcinogenesis. Methods miR-223 expression was assessed by quantitative reverse transcription polymerase chain reaction in a series of 280 gastroesophageal biopsy samples representative of the whole spectrum of phenotypic changes involved in both carcinogenetic cascades. The results were further validated by in situ hybridization on multiple tissue specimens obtained from six surgically treated gastroesophageal adenocarcinomas. miR-223 expression was also assessed in plasma samples from 30 patients with early stage (ie, stages I and II) gastroesophageal adenocarcinoma and relative controls. Results In both gastric and esophageal models, miR-223 expression significantly increased along with the severity of the considered lesions (analysis of variance, P  <   .001). Among atrophic gastritis and long-segment Barrett esophagus samples, miR-223 overexpression was significantly associated with the score of intestinal metaplasia. miR-223 plasma levels were significantly upregulated in patients with cancer compared with controls ( t test, both P  <   .001). Conclusions miR-223 early upregulation observed in tissue samples and its diagnostic value in discriminating patients with early adenocarcinoma by plasma testing provide a solid rationale for further exploring the diagnostic reliability of this microRNA as a novel biomarker in gastroesophageal adenocarcinoma secondary prevention strategies.
volume: Volume 135
issue: Issue 12
month: March
Appears in Collections:Circulation 2017

Files in This Item:
File Description SizeFormat 
2017 Circulation Volume 135 Issue 12 March (10).pdf1.82 MBAdobe PDFThumbnail
Download    Request a copy

Items in HannanDL are protected by copyright, with all rights reserved, unless otherwise indicated.